family with sequence similarity 236 member DGenealiases: []
Q-omics provides the consensus-scored FAM236D profile across patient tissues and cancer cell-line models. FAM236D expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, FAM236D is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, FAM236D RNA expression shows 8,141 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, BRCA, and THYM as cancer lineages where FAM236D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM236D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM236D survival associations across molecular data types. FAM236D RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM236D RNA expression–survival associations across cancer types. High FAM236D expression shows unfavorable associations in STAD, GBM, UCS, LUAD, MESO and KIRP. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for FAM236D RNA expression.
This table summarizes FAM236D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for FAM236D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM236D shows lower tumor expression in BRCA. The BRCA box plot shows higher FAM236D RNA expression in normal versus tumor tissue (log2 FC = −0.115, t-test p < 0.001).
This table shows molecular features associated with FAM236D in patient tissues and cancer cell lines. In patient samples, FAM236D shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
